Participating Companies

Abliva Ab
[ABLI:ST]
SKr142 MM MCap
Focused on rare and severe primary mitochondrial diseases (PMD). KL1333, a NAD+ regulator, to accelerate into pivotal studies in 2H21 based on positive FDA feedback; initial results from Ph1b in PMD patients exp. in 1Q21. NV354, an energy replacement therapy for Leigh Syndrome, in IND-enabling studies. [more information]

AcelRx Pharmaceuticals, Inc.
[ACRX]
$32 MM MCap
Launched DSUVIA (sufentanil sublingual tablet 30 mcg) in the US in 2019 for acute pain severe enough to require opioid analgesic (adult patients in certified medically supervised healthcare settings). Also developing Zalviso (Ph 3 completed) in the US as an innovative patient-controlled analgesia system for moderate-to-severe acute pain in medically supervised settings. [more information]

Achilles Therapeutics
cNeT (clonal neoantigen) process builds on TILs, combined with ability to identify pt-specific clonal neoantigens and generate personalized T-cell therapies. Sep19 GBP100 million Series B w/ RA, Syncona, Forbion, Invus, Perceptive + Redmile. [more information]

Adrenomed AG
Precision medicine, cardiovascular and Sepsis, Adrecizumab Ph 2, biomarker-guided, monoclonal antibody for septic shock; final data released late November:
Early application of Adrecizumab leads to a rapid and statistically significant improvement of fluid balance, systemic organ function and > 50% relative reduction of all cause mortality after 28 days and 90 days compared to placebo on top of SoC.
[more information]

Affibody
Proprietary Affibody® molecules and Albumod® platforms. Lead candidate ABY-035 is an IL-17 with multiple Ph 2 programs (PSO OLE PsA, axSpA, uveitis). Positive Ph2 52wk data in psoriasis with 2-yr OLE data expected in 2H21. Ph2 interim data for uveitis expected in 2022. AB-251 is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. $81M raised to date. [more information]

Affimed N.V.
[AFMD]
$415 MM MCap
NK cell engager AFM13 (CD30/CD16A) enrolling in a Phase 2 registration study in CD30-positive peripheral T cell lymphoma and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. [more information]

AM-Pharma B.V.
Raised $195M in equity and debt in 2019/2020 after results from Ph 2 in 300+ pts demonstrated robust significant improvement of 40%+ OS in recAP group. TL safety & futility analysis on first 400 pts Q1 2022. Expects to complete tgt enrollment & announce primary endpoint data of 28-day all-cause mortality in 2023, or as early as 2022 based on interim analyses. [more information]

Amarin Corporation
[AMRN]
$734 MM MCap
Commercializing Vascepa, the first and only pure EPA omega-3 fatty acid approved to lower triglyceride levels in adults. Presented (+) data from REDUCE-IT CV Outcomes trial at AHA. First 9mo rev’s of 2020 ~$450M. [more information]

Apexigen
CD40 agonist mAb; 170+ pts dosed (mono & combi settings). 7 ongoing Ph 2s, undisclosed ocular disease program in Ph 3. AACR: Ph 1b data (w/Parker Inst); collabs w/BMY, MDACC, Yale, et al [more information]

Aptorum Group
[APM]
$47 MM MCap
Hong Kong based, US listed company focused on generating late stage clinical candidates by developing already approved drugs for new orphan indications, as well as infectious diseases.
[more information]

Arcellx
[ACLX]
$785 MM MCap
A clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx's lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute mye [more information]

AsclepiX Therapeutics
Ophthalmology company using computational biology to identify potent peptide regulators of vascular homeostasis. The lead clinical candidate, integrin regulating peptide AXT107 (gersizangitide), has a novel mechanism of action that inhibits neovascularization, reduces vascular permeability and suppresses inflammation. In June 2020, Perceptive Xontogeny Venture Fund led the $35 million Series A financing with participation from existing investors Rapha Capital Management and Barer & Son Capital. [more information]

AxoGen
[AXGN]
$364 MM MCap
Global leader in development and marketing of innovative surgical solutions for the peripheral nerve injury market. Guidance for 2021 revenue is $127M-$129M with expected 2021 Gross Margin remaining above 80%. Lead product Avance Nerve Graft is a processed, human allograft for bridging nerve gaps of up to 70 mm. [more information]

Bellus Health
[BLU]
$1,001 MM MCap
BELLUS Health is developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. BELLUS' lead product candidate, BLU-5937, is being developed for the treatment of chronic cough (Phase IIb SOOTHE pre-planned interim in Sept. 2021; topline readout in 4Q21) and chronic pruritus (Phase II BLUEPRINT readout 4Q21). [more information]

BerGenBio
[BGBIO:OS]
NKr979 MM MCap
Developing first-in-class selective Axl kinase inhibitors for liquid and solid cancers, lead candidate is bemcentinib (BGB324) in four company-sponsored trials. [more information]

Biohaven Pharmaceuticals, Inc
[BHVN]
$10,260 MM MCap
Commercial-stage, focused on neurological & neuropsychiatric diseases; CGRP receptor antagonist, glutamate modulation, and MPO platforms. NURTEC® ODT approved 1Q20 acute treatment of migraine and 1Q21 preventive treatment of migraine; $136m 3Q21 revenues. [more information]

BioShin
Wholly owned subsidiary of Biohaven Pharmaceuticals. Shanghai-based, led by ex-BMY exec and Biohaven’s Chief of Corp Strategy & BD, Donnie McGrath, Bioshin aims to develop and commercialize Biohaven’s late-stage migraine and neurology portfolio in China and other APAC markets. [more information]

BioXcel Therapeutics, Inc.
[BTAI]
$348 MM MCap
BXCL501 (sublingual dexmedetomidine): Met primary, key secondary and exploratory endpoints in two pivotal Phase 3 trials for the for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). Phase 1b/2 trial (TRANQUILITY) ongoing for the acute treatment of agitation associated with geriatric dementia. [more information]

CalciMedica
Focused on CRAC channel for the treatment of acute and severe inflammatory diseases. CalciMedica’s lead compound Auxora has delivered promising Phase 2 results in severe COVID-19 pneumonia and acute pancreatitis. A Phase 2/3 clinical trial of Auxora in up to 400 patients with severe COVID-19 pneumonia is ongoing, and a Phase 2b trial of Auxora in patients with acute pancreatitis and a dose escalating phase 2 study in ventilated ARDS patients with COVID-19 and other pneumonia are expected to commence soon. [more information]

CASI Pharmaceuticals Inc.
[CASI]
$41 MM MCap
Launched EVOMELA® (melphalan for injection, multiple myeloma) in August '19, only melphalan commercially available in China: $7.1M 2Q21 revenues/guiding FY 2020 of over 80% growth. Co-commercial asset CNCT-19/CD19 CAR-T (partnered w/ Juventas): ongoing Ph 2 trials in B-NHL and B-ALL. Dosed 1st patient in Ph 1 study for CID-103 (anti-CD38 mAb) in EU in June 2021. [more information]

Catalyst Pharmaceuticals, Inc.
[CPRX]
$707 MM MCap
Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. [more information]

Celularity
[CELU]
$514 MM MCap
Celularity, headquartered in Florham Park, NJ, is a clinical-stage biotechnology company focusing on cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies. Celularity has a heritage as a former cell-therapy business unit of Celgene. [more information]

Clerio Vision, Inc.
Novel ophthalmic technology to treat refractive error addressing multi-billion markets in contact lenses (presbyopia, astigmatism, myopia, myopia progression) and corneal vision correction (non surgical flapless laser solution). Omnifocal contact lens presbyopia 510k submission and myopia progression clinical data in 2H2022. Based on Nobel Prize winning femto-second laser technology developed by Bausch & Lomb and the University of Rochester. [more information]

CureVac AG
[CVAC]
$2,637 MM MCap
German mRNA company with a diversified pipeline; Ph 2a trial ongoing with COVID-19 vaccine candidate, CVnCoV. Global Ph 2/3 trial enrolling approx. 36,500 participants with results expected 1Q21. Three other programs in Ph 1: CV8102 (cutaneous melanoma, adenoidcystic carcinoma, squamous cell cancer of skin, head & neck), CV9202 (NSCLC) and CV7202 (Rabies). mRNA-based antibody delivery deal with Genmab (Dec'19). Other strategic partnerships include GSK and CRISPR Tx. [more information]

Enko Chem
The company specializes in discovering small molecules for the control of agriculturally important pests, herbs and fungus that damage the crop by producing toxic compounds and decrease the quality of the crop, enabling farmers to maximize resource efficiency and eliminate or minimize product hazards to create durable programs for agriculture productivity. [more information]

ESSA Pharma Inc.
[EPIX]
$115 MM MCap
Focused on developing novel therapies for the treatment of prostate cancer. ESSA’s lead clinical candidate, EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor, with Ph 1 monotherapy data expected in 1H 2022. The company has also established clinical collaborations with JNJ, Astellas, and Bayer. [more information]

Exicure
[XCUR]
$16 MM MCap
Cavrotolimod (AST-008) in Ph2 trials for patients with Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, with Ph1b data presented at AACR 2020. XCUR-FXN in preclinical development for patients with Friedreich's Ataxia, using genetically targeted SNA therapies to remove FXN transcription blockage. [more information]

Faraday Pharmaceuticals
Chronic and acute agents to prevent cardiac and skeletal muscle loss by modulating neurohumoral pathways and restoring metabolic flexibility: lead candidate FDY-5301 Ph 3 ready for reperfusion injury following heart attack (AMI). $57M raised to date from Arch Venture Partners, Polaris Partners, WRF, Osage [more information]

Galera Therapeutics
[GRTX]
$39 MM MCap
Clinical stage biopharmaceutical company focusing on transforming radiotherapy in cancer. Final data with 1 year+ follow up on all patients for GC4419 in pancreatic cancer announced in 3Q21. Topline data from GC4711 in NSCLC expected in 1H22. Topline data from GC4711 in NSCLC expected in 1H22. [more information]

GENFIT SA
[GNFT]
$167 MM MCap
Ipsen licensed lead candidate ELATIVE (elafibranor) for €120M upfront payment, up to €360M in potential milestones, and double-digit royalties (tiered up to 20%).
See Phase 3 ELATIVE enrollment completion in 1Q22 and Phase 1 clinical data for nitazoxanide (acute chronic liver failure) by 3Q22 [more information]

Geron Corporation
[GERN]
$532 MM MCap
Focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in myeloid hematologic malignancies. Geron is currently conducting two ongoing registration-enabling Ph 3 clinical trials: (i) IMerge Phase 3 in Low or Intermediate-1 risk myelodysplastic syndromes, or lower risk MDS, and (ii) IMpactMF in Intermediate-2 or High-risk myelofibrosis, or refractory MF. Geron expects top-line results for IMerge Phase 3 to be available at the beginning of January 2023. [more information]

HaemaLogiX
Proprietary, differentiated B cell targets engaged via antibody and CAR-T programs
KappaMab & LambdaMab target activated plasma cell antigens (KMA/LMA); KappaMab plus RevDex vs. RevDex Ph 2b in MM, data 1H20; Kappa CAR-T Ph 1 Q120 in MM; Capacity for dual-targeting via CD-19, BCMA, etc; LambdaMab in preclinical for amyloidosis [more information]

Hangzhou Chance Pharmaceuticals
Chance focuses on inhalation products with proprietary technologies. [more information]

Heidelberg Pharma AG
[HPHA:DB]
€163 MM MCap
ATAC platform to develop novel cancer treatments with a unique mode of action killing both inactive and dividing cancers cells and overcoming tumor resistance mechanisms. Lead product HDP-101, for blood cancer, is expected to start clinical dev' end of 2021. Out-licensing the ATAC technology using the partners’ antibodies to create new ATACs and expect long term income streams and early technology validation. [more information]

Humanigen Inc.
[HGEN]
$136 MM MCap
results of NIH Phase 2/3 study in COVID that may serve as basis for EUA, BLA, or both in the U.S. initiation and interim assessment of Phase 2/3 trial for prevention/treatment of acute GVHD, initiation of Phase 3 with CAR-T and presentation of top-line data from some patients at ASH 2022. [more information]

Immatics NV
[IMTX]
$539 MM MCap
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. [more information]

Impact Therapeutics Inc
IMPACT and Junshi Biosciences established a 50:50 joint venture that focuses on the development and commercialization of Senaparib in China. The JV is currently conducting a Phase II pivotal study and a Phase III study of Senaparib in ovarian cancer third-line treatment and first-line maintenance treatment in China. [more information]

IN8bio, Inc.
[INAB]
$42 MM MCap
First company to advance genetically-modified gamma-delta T cells into clinical trials with its DeltEx Platform, based on ex-vivo expanded and activated gamma-delta T cells. Two investigator-initiated Phase 1 clinical trials are underway for lead product candidates: INB-200 for newly diagnosed glioblastoma and INB-100 for acute leukemia. [more information]

Inozyme Pharma
[INZY]
$202 MM MCap
Lead candidate INZ-701 is an enzyme replacement therapy designed to treat calcification disorders of the circulatory system, bone and kidney for which insufficient treatment options currently exist. ENPP1 and ABCC6 deficiency Phase 1/2 initiations expected H1'2021 with results H2'2021. [more information]

Invetx
Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. The Invetx team of highly experienced R&D leaders from both human biotech and animal health is supported by best-in-class biotechnology partners and an extensive network of industry experts, veterinary scientists and clinicians. Invetx is a private company headquartered in Boston, Massachusetts. [more information]

Iovance Biotherapeutics
[IOVA]
$1,726 MM MCap
Developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL) for the treatment of solid tumors. TIL therapy is a highly personalized approach in which patients receive a one-time treatment with their own expanded and rejuvenated T-cells to treat cancer. BLA expected in 1H22 following completion of pivotal study of Lifileucel/LN-144 for treatment of Melanoma. [more information]

ISA Pharmaceuticals BV
is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. [more information]

Junshi Biosciences
[1877.HK]
Has a diversified R&D pipeline comprising over 21 drug candidates with therapeutic areas covering cancer, metabolic, autoimmune, neurological, and infectious diseases. Lead candidate, Toripalimab (JS001), reached over 1B RMB in sales, and expanded indications into nasopharyngeal carcinoma/urothelial carcinoma. Other product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai [more information]

Kadmon Holdings, Inc.
[KDMN]
$1,696 MM MCap
Aug 30 PDUFA data for belumosudil (cGVHD) following positive primary analysis results (May 2020); observed ORRs of 73% and 74% in 200mg QD and 200mg BID arms, respectively. Initiating 12-15 pt open-label Ph 2 in patients w diffuse cutaneous systemic sclerosis in Q1 2021. First 3-pt dose cohort successfully completed in ongoing dose-escalation Ph 1 (anti-PD-L1/IL-15 fusion protein) in patients w metastatic or locally advanced solid tumors; enrollment ongoing in next dose level. Continuing IND-enabling activi [more information]

KAHR
KAHR is developing novel immuno-oncology fusion proteins. DSP107, is a CD47-41BB targeting compound aimed at targeting cancer cells' innate defenses and activating localized response. Activated pathways include innate and adaptive immunity. [more information]

Kaleido BioSciences
[KLDO]
$3 MM MCap
Harnessing proprietary small molecule chemistry platform to develop microbiome metabolic therapies (MMT) in indications spanning I-O, nitrogen metabolism, metabolic diseases, and CNS. Topline data expected in 1Q21 from multi-center (K031) clinical study of KB109 in outpatients with mild-to-moderate COVID-19 disease and from study with Massachusetts General Hospital (K032). Topline data from clinical study of KB295 in approximately 30 patients with mild-to-moderate UC expected mid-2021, topline data from UNL [more information]

Keros Therapeutics
[KROS]
$626 MM MCap
A leader in understanding the role of the TGF-Beta family of proteins that is a master regulator of RBC and platelet production as well as the growth, repair and maintenance of muscle and bone. Lead protein therapeutic product candidate, KER-050, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome (MDS) and myelofibrosis, with additional data expected from Part 1 of Ph 2 study in MDS being presented at ASH 2021. [more information]

Kineta Inc.
Kineta (Private) - wholly owned preclinical anti-VISTA (innate immune target) antibody reprograms the tumor microenvironment and is differentiated from other immunotherapies by blocking suppressive cells in cold tumors. $360M+ deal with Genentech for KCP506, Ph1 non-opioid for chronic pain. [more information]

Kintor Pharma
[9939.HK]
Two Ph3s ongoing in China: Pivotal monotherapy and combo with abiraterone and a Ph2 ongoing in US for mCRPC (with breast and other AR-driven cancers behind). Additional pipeline includes a topical AR for alopecia and earlier-stage targets including ALK-1 and hedgehog. [more information]

Landos Biopharma
[LABP]
$32 MM MCap
Pipeline targets novel immunometabolic pathways, including LANCL2, NLRX1 and PLXDC2. Lead asset omilancor is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis (completed Ph2), Crohn’s disease (Ph2) and Eosinophilic Esophagitis that targets the LANCL2 pathway [more information]

LianBio
LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics. [more information]

Lineage Cell Therapeutics Inc.
[LCTX]
$214 MM MCap
Cell therapy company with 3 clinical programs 1) OpRegen, an RPE transplant therapy in Ph1/2a development for the treatment of dry-AMD. 2) OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries with Orphan and RMAT designations. 3) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Ph 1 for NSCLC conducted by CRUK. [more information]

Marker Therapeutics
[MRKR]
$28 MM MCap
Focused on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. [more information]

Maxcyte
[MXCT:LN]
global cell therapy company providing proprietary non-viral cell engineering technology for the next generation of cell-based therapies including gene editing and immuno-oncology. MaxCyte may be seen as a play on the cell therapy market with its blue chip client base. [more information]

MEI Pharma, Inc.
[MEIP]
$86 MM MCap
Broadening zandelisib development activity includes addition of marginal zone lymphoma arm to TIDAL to support expansion of an accelerated approval strategy if successful, the initiation of a Phase 3 study in second line follicular and marginal zone lymphomas in mid-2021, and plans to support select investigator-initiated trials, initially in first-line DLBCL. [more information]

Merus NV
[MRUS]
$966 MM MCap
Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. [more information]

Minoryx Therapeutics
Oral PPARg agonist, leriglitazone, demonstrated clinical benefit of significantly reducing progression of cerebral lesions and myelopathy symptoms in pivotal Phase 2/3 study results in X-ALD pts w Adrenomyeloneuropathy (AMN), 6MWT endpoint was not met; ongoing discussions with regulators re: approval. Phase 2 data in Friedrich’s Ataxia showed modulation of the Frataxin pathway and restoration of the bioenergetics deficits in FRDA patients. VC investors include Kurma, Ysios, Fund+, Roche, Idinvest, etc
[more information]

Monte Rosa Therapeutics
[GLUE]
$478 MM MCap
Next-generation molecular glue-based targeted protein degradation platform developing small molecule therapeutics that selectively degrade disease-causing proteins. Targeting the undruggable proteome in oncology and non-oncology indications via AI based degron prediction. Lead program focused on GSPT1, a key regulator and vulnerability of Myc-induced translational addiction. [more information]

Nanobiotix SA
[NBTX]
$141 MM MCap
Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. [more information]

Neoleukin Therapeutics
[NLTX]
$44 MM MCap
Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. NL-201 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory cancer and the company is expecting interim data in 2022. [more information]

NexImmune, Inc.
[NEXI]
$38 MM MCap
Multi-antigen-specific T cell therapy. Synthetic nanoparticles decorated w a combo of multiple tumor relevant antigens and co-stimulatory signals engaging directly w targeted T cells. Two Ph 1's ongoing. [more information]

NorthSea Therapeutics
Focused on developing SEFAs for the treatment of NASH and other metabolic disorders. Lead product, icosabutate has been found safe and effective in two prior phase 2 clinical studies for treatment of hypertriglyceridemia and mixed dyslipidemia and is currently in clinical development for NASH. The icosabutate phase 2b ICONA NASH trial is scheduled to readout in the first quarter of 2023. Two additional SEFAs are in clinical development; SEFA 1024 is in phase 1 to be developed for dyslipidemia and SEFA 6179, [more information]

NRx Pharmaceuticals, Inc.
[NRXP]
$39 MM MCap
Leading Relief Therapeutics Ph 2 trial of Aviptadil to treat COVID-19 induced ARDS in the US. In Phase 3 with readout expected mid-January 2021. Also developing first Glx targeted antidepressant to address suicidality in bipolar depression. NRX-101 is in Ph 2b/3 development, (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w Acute Suicidal Ideation and Behavior. [more information]

Oncopeptides AB
[ONCO:ST]
SKr965 MM MCap
Developing targeted therapies for patients facing hard-to-treat hematological diseases, with focus on next generation candidates including OPD5 (Ph1) and OPDC3 based on proprietary peptide drug conjugate platform. EMA application pending for melflufen (melphalan flufenamide) in relapsed refractory multiple myeloma; CHMP opinion expected in Q2 2022. [more information]

OncoResponse
In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. [more information]

Oncorus
[ONCR]
$35 MM MCap
The company's lead program ONCR-177 is a Ph1 oHSV with complementary payloads (PD1, CCL4, IL12, FLT3, CTLA4) to encourage immune stimulation, with readout guided for 2H21. [more information]

OnKure Therapeutics, Inc.
Developing epigenetic cancer therapies including HDAC inhibitors. Lead asset OKI-179 is a class 1 HDAC inhibitor in Ph 1. [more information]

PharmaMar SA
[PHM:ES]
Revenue generating with marine-derived and novel MoA oncology products. Yondelis (soft tissue sarcoma and ovarian cancer) commercialized with direct sales-force in EU and partnership in US with Janssen. Signed licensing agreement with Jazz Pharma for lurbinectedin in the US - upfront payment of $200M, $100mm on approval and up to $550M sales milestones. [more information]

Pharming Group NV
[PHARM:AS]
€495 MM MCap
recent in-license from Novartis of late stage drug Leniolisib for APDS (ultra-rare immunodeficiency condition), rhC1INH for new larger indications including COVID-19, pre-eclampsia, AKI and additional pipeline product from technology platform: recombinant alpha-Glucosidase for Pompe disease. [more information]

Photocure ASA
[PHO:OS]
NKr2,823 MM MCap
Lead product Hexvix®/Cysview® improves detection of bladder cancer under blue light cystoscopy (BLC). Approved in over 30 countries, Hexvix®/Cysview® is directly sold in the US and EU, and through worldwide partnerships. Photocure reported US$37.8M revenue in 2021 and expects up to $250M from license of non-core asset CEVIRA® to Asieris. Headquartered in Oslo, Norway, Photocure is 20% owned by US investors (significant increase over past few years) and commercially focused on US market. [more information]

Pliant Therapeutics, Inc.
[PLRX]
$277 MM MCap
Focused on discovering and developing therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, and primary sclerosing cholangitis. Second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with NASH, which Pliant has partnered with Novartis. [more information]

PROSION
A pharmaceutical drug discovery company with proline derived modules (ProMs) as the world’s first PRM structure mimicking building blocks. The company develops a new class of drugs and is able to address yet undruggable considered targets that are related to various indications. For its first of many use-cases, PROSION has already shown a remarkable in vivo effect of its ProM-based anti-metastatic inhibitor – both in pancreatic and breast cancer xenograft rodent models. [more information]

Protagonist Therapeutics
[PTGX]
$411 MM MCap
Proprietary peptide technology platform to develop oral targeted therapy-based drugs and injectables for rare diseases. PTG-300 injectable hepcidin mimetic Ph 2 trials ongoing in polycythemia vera and hereditary hemochromatosis; positive updated Ph 2 results in PV presented at ASH 2020. PN-943 oral GI-restricted alpha-4-beta-7 antagonist Ph 2 in ulcerative colitis study sites activated; PTG-200, partnered w/ Janssen, oral GI-restricted IL-23R antagonist Ph 2 Crohn’s disease study ongoing. [more information]

R2 Technologies
Headquartered in Silicon Valley, R2 focuses on the development and commercialization of groundbreaking technologies for aesthetic providers and consumers. Based on the licensed exclusive intellectual property from Massachusetts General Hospital to modulate melanin production, R2 Technologies was founded in 2014 by Pansend Life Sciences and Blossom Innovations. [more information]

Rigel Pharmaceuticals
[RIGL]
$188 MM MCap
Focused on hematologic disorders, cancer, and rare immune diseases. Rigel's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase inhibitor for the treatment of chronic immune thrombocytopenia. The Company is also targeting SYK in Warm Antibody AIHA and COVID-19, interleukin receptor-associated kinases 1&4 in oncology and immune diseases, and receptor-interacting serine/threonine-protein kinase 1 in CNS diseases. [more information]

Ryvu Therapeutics
[RVU:WAR]
Developer of targeted oncology therapies including hematology/solid tumors. RVU120 is wholly-owned first-in-class oral CDK8/19 inhibitor in Phase I for AML/MDS Small molecule, synthetic lethality platform in pre-clinical development including novel targets WRN and PRMT5.
[more information]

Savara Inc.
[SVRA]
$172 MM MCap
Clinical-stage biopharma focused on rare respiratory diseases; molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF), is in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP); top-line data from the double-blind period of the Company’s Phase 3 trial (IMPALA 2) is anticipated at the end of 2Q 2024. [more information]

Secarna Pharmaceuticals GmbH
Secarna's uniquely efficient LNAplus™ discovery process is fueled by their proprietary and streamlined Oligofyer™ bioinformatics systems large in-house cell library and own in vitro screening assays. [more information]

Sol-Gel Technologies Ltd.
[SLGL]
$102 MM MCap
Commercializing branded generic topical drug products (skin diseases). Two positive Phase 3 programs, both with PDUFA dates in 2021: Epsolay has potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product for rosacea (PDUFA date on April 26th). Twyneo has potential to be the first acne treatment that contains fixed dose combination of BPO and tretinoin (PDUFA date on August 1st). [more information]

Sonnet Biotherapeutics, Inc.
[SONN]
$17 MM MCap
Utilizing a platform approach to develop immuno-oncology therapeutics featuring a proprietary fully human Albumin Binder capable of linking 1-2 different therapeutic targets. Sonnet's interleukin-based candidate has been shown to enhance pK (up to 10 fold) and improve tumor delivery with an increase in in vivo efficacy (30 fold) as demonstrated in a mice tumor model. [more information]

Spruce Biosciences
[SPRB]
$41 MM MCap
Focused on developing and commercializing novel therapies for rare endocrine disorders. The company’s lead product candidate, Tildacerfont, is currently being evaluated for the treatment of classic adult congenital adrenal hyperplasia (CAH), and in upcoming studies in pediatric classic CAH and Polycystic Ovary Syndrome (PCOS). [more information]

sterna biologicals
By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes to address related diseases more effectively. Sterna currently has four programs in phase 2 development. [more information]

Strongbridge Biopharma
[SBBP]
$136 MM MCap
Rare diseases; Keveyis for PPP revs ~21.7M for 2019 and $26 - $27M for 2020. Recorlev for endogenous Cushing's syndrome Ph 3 published with topline placebo-controlled Ph 3 3Q20. [more information]

Sutro Biopharma
[STRO]
$245 MM MCap
Focused on developing next generation antibody drug conjugates (ADCs) and other complex biologics for cancer. The company’s FolRα-targeting ADC (STRO-002) in ovarian cancer is currently in Ph 1 with dose-expansion data expected in 2H 2021. Enrollment is ongoing for CD74-targeting ADC (STRO-001) in the Ph 1 dose-escalation in B-cell malignancies. Sutro has three high value collaborations with BMS, Merck, and EMD Serono. [more information]

Syneos Health
[SYNH]
$7,480 MM MCap
Syneos Health® is an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial, work together to create customer success. Our unique Biopharmaceutical Acceleration Model delivers value across the small to mid-size to large customer continuum. [more information]

Teon Therapeutics
Pipeline of next-generation cancer therapeutics targeting GPCRs including a highly-specific A2B antagonist and EP4 antagonist, both slated to enter Phase 1b trials in 2021. [more information]

Utility Therapeutics
UTILITY has received the FDA’s QDIP (qualified infectious disease product) designation for both products and plans to file an NDA in 2021 for pivemecillinam for the treatment of uncomplicated UTIs. Pivmecillinam is currently recommended as a first-line therapy in the current IDSA (Infectious Disease Society of America) treatment guidelines for uncomplicated UTIs. [more information]

Vaccitech Plc
[VACC]
$195 MM MCap
Proprietary ChAdOx (prime) and MVA (boost) technology platform induces CD8+ T cell and antibody immune responses to treat and prevent infectious diseases and cancer. Broad therapeutic pipeline. Encouraging Ph1/2 interim efficacy data for VTP-300 (HBV functional cure) and VTP-200 (high-risk HPV therapeutic) efficacy data expected 4Q2022. $15M royalty revenue during Q42021 from AstraZeneca's commercial sales of Vaxzevria® (out-licensed ChAdOx COVID-19 vaccine) [more information]

Vericel Corporation
[VCEL]
$1,208 MM MCap
Advanced cell therapy; marketing MACI (cartilage repair) and Epicel (skin replacement) in TAMs of $2b+. Q3 MACI and Epicel revs of $31.1m. Reported record third quarter MACI revenue and total revenues, and the second highest quarterly Epicel revenue in history. NexoBrid PDUFA date of June 29, 2021. [more information]

Verrica Pharmaceuticals
[VRCA]
$60 MM MCap
A dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's lead product candidate, VP-102, is a GMP-controlled formulation of cantharidin delivered via a single-use applicator for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts. The Company is also developing treatments for plantar warts (VP-103) and basal cell carcinoma (LTX-315). [more information]

Viela Bio
[VIE]
$2,913 MM MCap
UPLINZA® (inebilizumab, anti-CD19 mAb) on the market for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Additional trials with inebilizumab ongoing, including Ph 3 trials in myasthenia gravis and IgG4-related disease. VIB7734, anti-ILT7 mAb, Ph 2 trial to initiate in 1H21. Ph 2 trials ongoing for VIB4920 (Anti-CD40L-Tn3 Fusion Protein) in Sjogren's Syndrome and kidney transplant rejection. [more information]

XOMA Corporation
[XOMA]
$238 MM MCap
Biotech royalty and milestone aggregator with portfolio of 70+ assets in >30 disclosed indications where R&D costs are borne by partners e.g. Roche's Faricimab (BLA filed for nAMD and DME 7/29/21) [more information]

Zentalis
[ZNTL]
$1,599 MM MCap
Developing best-in-class small molecule therapeutics targeting fundamental biological cancer pathways. WEE1 inhibitor for advanced solid tumors currently in Ph 2. ZN-c5, an oral SERD for breast cancer, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for NSCLC. [more information]